Patents by Inventor Christophe Morice

Christophe Morice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210230157
    Abstract: The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compounds and methods for their preparation.
    Type: Application
    Filed: May 17, 2019
    Publication date: July 29, 2021
    Inventors: Belinda HUFF, Courtney HOLLIS, Hamish TOOP, Nathan KUCHEL, Lorna Helen MITCHELL, Rajinder SINGH, Thomas AVERY, Celine MICHAUT-SIMON, Jean-Marie CONTRERAS, Christophe MORICE
  • Publication number: 20200392126
    Abstract: The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.
    Type: Application
    Filed: November 26, 2018
    Publication date: December 17, 2020
    Applicant: BIONOMICS LIMITED
    Inventors: Justin Anthony RIPPER, Patrick BAZZINI, Jean-Marie CONTRERAS, Nicolas FEICHTER, Christophe MORICE, Laurent SCHAEFFER, Cindy STAHL
  • Patent number: 9994518
    Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 12, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Kenneth Leavitt, Brendan Crowley, Ian M. Bell, Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen, Patrick Bazzini, Aurelie Fromeyer
  • Patent number: 9790173
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: October 17, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen
  • Publication number: 20170158628
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Application
    Filed: February 17, 2017
    Publication date: June 8, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: ANDREW HARVEY, THOMAS AVERY, DHARAM PAUL, JUSTIN RIPPER, BELINDA HUFF, RAJINDER SINGH, LAURENT SCHAEFFER, CHRISTOPHE JOSEPH, CHRISTOPHE MORICE, BRUNO GIETHLEN
  • Publication number: 20170152221
    Abstract: Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein “RIa”, “RIb”, “RIc”, “RId”, “RIe”, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
    Type: Application
    Filed: June 11, 2015
    Publication date: June 1, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: KENNETH LEAVITT, BRENDAN CROWLEY, IAN M. BELL, ANDREW HARVEY, THOMAS AVERY, DHARAM PAUL, JUSTIN RIPPER, BELINDA HUFF, RAJINDER SINGH, LAURENT SCHAEFFER, CHRISTOPHE JOSEPH, CHRISTOPHE MORICE, BRUNO GIETHLEN, PATRICK BAZZINI, AURELIE FROMEYER
  • Publication number: 20160376286
    Abstract: The present invention relates to a compound having the general formula II, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: June 15, 2016
    Publication date: December 29, 2016
    Inventors: Dirk CLASSEN-HOUBEN, Andrea WOLKERSTORFER, Oliver SZOLAR, Mark SMITH, Sung-Sau SO, Stephen CUSACK, Thierry LANGER, Bruno GIETHLEN, Christophe MORICE, Céline MICHAUT-SIMON, Laurence JUNG
  • Publication number: 20160367557
    Abstract: The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 22, 2016
    Inventors: Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Stephen CUSACK, Thibault SAUVAITRE, Céline SIMON, Christophe MORICE, Bruno GIETHLEN, Thierry LANGER, Mark SMITH, Sung-Sau SO, Dirk CLASSEN-HOUBEN, Helmut BUSCHMANN
  • Publication number: 20160362423
    Abstract: The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: August 26, 2016
    Publication date: December 15, 2016
    Inventors: Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Stephen CUSACK, Thibault SAUVAITRE, Céline SIMON, Christophe MORICE, Bruno GIETHLEN, Thierry LANGER, Mark SMITH, Sung-Sau SO, Dirk CLASSEN-HOUBEN, Helmut BUSCHMANN
  • Publication number: 20160297763
    Abstract: The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: April 6, 2016
    Publication date: October 13, 2016
    Applicants: F. HOFFMANN-LA ROCHE LTD, SAVIRA PHARMACEUTICALS GMBH, EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL)
    Inventors: Dirk CLASSEN-HOUBEN, Andrea WOLKERSTORFER, Oliver SZOLAR, Mark SMITH, Sung-Sau SO, Stephen CUSACK, Thierry LANGER, Bruno GIETHLEN, Christophe MORICE, Céline MICHAUT-SIMON, Chloe ZUBIETA
  • Patent number: 9434745
    Abstract: The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: September 6, 2016
    Assignees: Savira pharmaceuticals GmbH, F. Hoffmann-La Roche AG, European Molecular Biology Laboratory
    Inventors: Andrea Wolkerstorfer, Oliver Szolar, Norbert Handler, Stephen Cusack, Thibault Sauvaitre, Céline Simon, Christophe Morice, Bruno Giethlen, Thierry Langer, Mark Smith, Sung-Sau So, Dirk Classen-Houben, Helmut Buschmann
  • Publication number: 20150175534
    Abstract: The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of ?7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
    Type: Application
    Filed: August 1, 2013
    Publication date: June 25, 2015
    Inventors: Andrew Harvey, Thomas Avery, Dharam Paul, Justin Ripper, Belinda Huff, Rajinder Singh, Laurent Schaeffer, Christophe Joseph, Christophe Morice, Bruno Giethlen
  • Patent number: 8962627
    Abstract: The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: February 24, 2015
    Assignee: Prestwick Chemical, Inc.
    Inventors: Stephan Schann, Stanislas Mayer, Christophe Morice, Bruno Giethlen
  • Publication number: 20130317021
    Abstract: The present invention relates to a compound having the general formula (C), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Inventors: Andrea WOLKERSTORFER, Oliver Szolar, Norbert Handler, Stephen Cusack, Thibault Sauvaitre, Céline Simon, Christophe Morice, Bruno Giethlen, Thierry Langer, Mark Smith, Sung-Sau So, Dirk Classen-Houben, Helmut Buschmann
  • Publication number: 20130317022
    Abstract: The present invention relates to a compound having the general formula (A), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: May 23, 2013
    Publication date: November 28, 2013
    Applicants: European Molecular Biology Laboratory, F. Hoffmann-La Roche AG
    Inventors: Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Stephen CUSACK, Thibault SAUVAITRE, Céline SIMON, Christophe MORICE, Bruno GIETHLEN, Thierry LANGER, Mark SMITH, Sung-Sau SO, Dirk CLASSEN-HOUBEN, Helmut BUSCHMANN
  • Publication number: 20120277212
    Abstract: The present invention provides new oxime derivatives of the general formula (I), pharmaceutical compositions containing them and their use for the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals. This invention further provides new oxime derivatives of the general formula (I) consisting of modulators of nervous system receptors sensitive to glutamate, which makes them particularly suitable for the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. In particular embodiments, the new oxime derivatives of the invention are modulators of metabotropic glutamate receptors (mGluRs). The invention further provides positive allosteric modulators of mGluRs and more specifically positive alSosteric modulators of mGluR4.
    Type: Application
    Filed: October 29, 2010
    Publication date: November 1, 2012
    Applicants: PRESTWICK CHEMICAL, INC., DOMAIN THERAPEUTICS
    Inventors: Stephan Schann, Stanislas Mayer, Christophe Morice, Bruno Giethlen
  • Patent number: 8071590
    Abstract: A subject of the invention is the compounds of formula (I): wherein R1, R2, R3, R?3, R4, R?4, R5, R6 and R7 are as described in the application, in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: December 6, 2011
    Assignee: Vetoquinol SA
    Inventors: Sandrine Ropp, Christophe Morice, Bruno Giethlen, Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Francoise Leblanc, Marc Schneider
  • Patent number: 7713965
    Abstract: A subject of the invention is the compounds of formula (I): in which either R1 represents H, OH, NH2, —(CH2)m—NRaRb(m=0.1 or 2), Ra and Rb represent H, linear, branched or cyclic (C1-C6) alkyl, (C3-C6) cycloalkyl-(C3-C6)— alkyl, Rc, S(O)2Rc, C(O)Rc, S(O)2Rd or C(O)Rd; or Ra and Rb with N form an Rc radical; Rc represents a saturated, unsaturated or 5- or 6-members aromatic ring, containing 1 to 4 heteroatoms chosen from N, O and S, optionally substituted; Rd represents a linear, branched or cyclic (C1-C6) alkyl, optionally substituted by 1 to 4 halogens; or R1 represents Rc or CHReRc or CHReRd; Re represents H, OH, NH2, NH—(C1-C6)-alk or N-(C1-C6)-alk2, or NH—(C1-C7)-acyl or NHRc; R2 represents H, (CH2)m—NRaRb, Rc, CHReRc or CHReRd, and R?2 represents H.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 11, 2010
    Assignee: Vetoquinol SA
    Inventors: Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Françoise Leblanc, Marc Schneider, Sandrine Ropp, Christophe Morice, Bruno Giethlen
  • Publication number: 20100009980
    Abstract: A subject of the invention is the compounds of formula (I): wherein R1, R2, R3, R?3, R4, R?4, R5, R6 and R7 are as described in the application, in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.
    Type: Application
    Filed: June 23, 2009
    Publication date: January 14, 2010
    Applicant: Vetoquinol SA
    Inventors: Sandrine Ropp, Christophe Morice, Bruno Giethlen, Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Francoise Leblanc, Marc Schneider
  • Publication number: 20090221565
    Abstract: A subject of the invention is the compounds of formula (I): in which either R1 represents H, OH, NH2, —(CH2)m—NRaRb(m=0.
    Type: Application
    Filed: February 27, 2009
    Publication date: September 3, 2009
    Applicant: Vetoquinol SA
    Inventors: Sandrine Ropp, Christophe Morice, Bruno Giethlen, Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Francoise Leblanc, Marc Schneider